• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Johnson & Johnson’s global pharma sales up 19% in Q1

April 17, 2018 By Sarah Faulkner

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) today reported first-quarter sales and earnings results, topping analysts’ expectations on Wall Street.

The company’s pharmaceutical business delivered “robust growth,” chairman & CEO Alex Gorsky said in a statement; worldwide global sales grew 19.4% to $9.8 billion for the first quarter compared to same period in 2017.

Domestic sales were up 9.9% and international revenues grew 33.1% in the first quarter, J&J touted. The company said that its results were driven by the launch of new products, including a multiple myeloma therapy, Darzalex, a once-daily therapy for patients with certain B-cell malignancies, Imbruvica, and a treatment for adults with moderate to severe plaque psoriasis, Tremfya.

J&J also landed a series of regulatory wins in the first quarter of 2018, like a positive opinion issued by the Committee for Medicinal Products for Human Use for Juluca – the first single-pill, two-drug regimen for people with HIV.

Reflecting its effort to withdraw from the diabetes business, sales for J&J’s diabetes division fell -15% to $339 million in Q1.

Combining all of its divisions, the New Brunswick, N.J.-based healthcare giant posted profits of $4.37 billion, or $1.60 per share, on sales of $20.0 billion for the three months ended March 30, for a bottom-line slide of -1.2% on sales growth of 12.6% compared with Q1 2017.

Adjusted to exclude one-time items, earnings per share were $2.06, 5¢ ahead of Wall Street’s consensus, where analysts were looking for sales of $19.38 billion.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS